Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Inclusion Criteria: Base Study: * Is healthy and is judged to be in good physical health based on medical history and physical examination * Has provided written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research * Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes * Can read, understand, and complete the electronic vaccination report card (eVRC) * Has had at least 1 lifetime sexual partner Extension Study: * Participants may continue in the Extension Study if Inclusion Criteria #1 and #4 are still met, and the participants was in either the placebo group in the Base Study or the vaccine group in the Base Study but did not complete the vaccination series * Provides documented consent for the Extension Study Exclusion Criteria: Base Study: * Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV related head and neck cancer * Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion * Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease * Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C) wit…